Custom Search


Wednesday 01 March 2006

Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease.

By: Casquero A, Barroso A, Fernandez Guerrero ML, Gorgolas M.

Ann Hematol 2006 Mar;85(3):185-7

Several approved therapies for multicentric Castleman disease (MCD) cannot be uniformly applied due to intolerable side effects. There is also a high percentage of recurrence of this disease despite treatment. Rituximab may be effective in controlling MCD in a subset of patients. This paper includes a brief case report and an extensive review of previously published cases. We observed an aggravation of concomitant cutaneous Kaposi sarcoma, and hypothesize that rituximab could have exacerbated it.

Use of this site is subject to the following terms of use